PM recalls his ‘chaiwala’ past during interaction with divyang man from Goa
Prime Minister Narendra Modi met Indian COVID-19 vaccine manufacturers on Saturday, within two days of the country achieving a key milestone of administering 100 crore doses of the jabs, official sources said.
During the meeting, Modi discussed various issues including furthering the vaccine research, sources said.
Representatives from seven vaccine makers — Serum Institute of India, Bharat Biotech, Dr Reddy’s Laboratories, Zydus Cadila, Biological E, Gennova Biopharma and Panacea Biotech — participated in the meeting.
Union Health Minister Mansukh Mandaviya and Union Minister of State for Health Bharati Pravin Pawar were also present in the meeting.
The cumulative COVID-19 vaccine doses administered in the country has exceeded 101.30 crore, according to the latest health ministry data.
On October 21, India achieved a major milestone in its vaccination programme against COVID-19 as the cumulative vaccine doses administered in the country surpassed the 100-crore mark, resulting in celebratory events across various parts.
More than 75 per cent of India’s adult population has received at least one dose of COVID-19 vaccine, with nine states and union territories administering the first dose to all eligible people.
Over 31 per cent of the country’s around 93 crore adults have been administered both doses, according to health ministry officials.
So far, all adult population in nine states and union territories — Andaman and Nicobar Islands, Chandigarh, Goa, Himachal Pradesh, Jammu and Kashmir, Lakshadweep, Sikkim, Uttarakhand and Dadra and Nagar Haveli — have received at least one dose of the Covid vaccine.
Three vaccines — Covishield manufactured by Serum Institute of India, Bharat Biotech’s Covaxin and Sputnik V — are currently being used in the country’s Covid vaccination drive.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
